Transfusion medicine for the pediatrician

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1211-1238

  Quirolo, Keith C ^a,b  

^a UCSF Medical Center at Parnassus   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZIRIDINE; BLOOD SUBSTITUTE; PSORALEN; RIBOFLAVIN;

BABESIOSIS; BACTERIUM CONTAMINATION; BACTERIUM DETECTION; BLOOD ANALYSIS; BLOOD BANK; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; BORRELIA BURGDORFERI; CREUTZFELDT JAKOB DISEASE; CYTOMEGALOVIRUS; EHRLICHIOSIS; EPSTEIN BARR VIRUS; ERYTHROCYTE; ERYTHROCYTE PRESERVATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOMODULATION; LUNG INJURY; PEDIATRICIAN; PLASMODIUM; PRACTICE GUIDELINE; REVIEW; RICKETTSIA RICKETTSII; SCREENING TEST; THROMBOCYTE; TICK BORNE DISEASE; TRYPANOSOMA CRUZI; VIRUS DETECTION;

BLOOD DONORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CHILD; COMMUNICABLE DISEASES, EMERGING; DISEASE TRANSMISSION; HUMANS; RISK FACTORS; SAFETY;

EID: 0036979488     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00090-1     Document Type: Review

References (83)

1. Center for Biologics Evaluation and Research (CEBER). Current good manufacturing practices (21CFR 606): implementation May 7, 2001, and Federal Register Jan 1973. Sec.230.120: Human Blood and Blood Products as Drugs (CPG 7134.02).
2. Ulrich PP, Bhat RA, Seto B, et al. Enzymatic amplification of hepatitis B virus DNA in serum compared with infectivity testing in chimpanzees. J Infect Dis 1989;160:37-43.
3. Lubin DM. Universal RBC'S. Transfusion 2000;40:1285-9.
4. Counsel of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med 2001;11:149-75.
5. Busch MP, Kleinman SH. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Transfusion 2000;40:143-59.
6. Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000;40:1165-8.
7. Kleinman SH. Hepatitis G virus biology, epidemiology, and clinical manifestations: implications for blood safety. Transfus Med Rev 2001;15:201-12.
8. Busch MP. Closing the windows on viral transmission by blood transfusion. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda (MD): American Association of Blood Banks; 2001. p. 33-54.
9. Jackson B, AuBuchon J, Busch M. Cost-effectiveness of nucleic acid testing for HIV and HCV in donated blood [abstract]. Transfusion 2000;40(Suppl):S138-9.
10. Dodd RY. Germs, gels, and genomes: a personal recollection of 30 years in blood safety testing. In: Stramer SL, editor. Blood safety in the new millennium. Bethesda (MD): American Association of Blood Banks; 2001. p. 97-122.
11. Stramer SL. Reentry for donors deferred because of HIV or HVC NAT or serological test results. Presented for BPAC June 4, 2001.
12. Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
13. Kleinman SH, Busch MP. HBV: amplified and back in the spotlight. Transfusion 2001;41:1081-5.
14. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative roll of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A 1984;812:534-7.
15. Gessain A, Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1992;117:933-46.
16. Mochizuki M, Watanabe T, Yamaguchi K, et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 1992;83:236-9.
17. Lee HH, Swanson P, Rosenblatt JD, et al. Relative prevalence and risk factors of HTLV-I and HTLV-II infection in U.S. blood donors. Lancet 1991;337:1435-9.
18. Busch MP, Switzer EL, Murphy EL, et al. Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results. Transfusion 2000;40:443-9.
19. Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. J Infect Dis 1997;176:1468-75.
20. Perez P, Salmi R, Follea G, et al. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study. Transfusion 2001;41:862-72.
21. Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two years. BMJ 1999;319:16-9.
22. Williamson L, Cohen H, Love E, et al. The serious hazards of transfusion (SHOT) initiative: the UK approach to haemovigilance. Vox Sang 2000;78(Suppl 2):291-5.
23. Michell KM, Brecher ME. Approaches to the detection of bacterial contamination in cellular blood products. Transfus Med Rev 1999;13:132-44.
24. McDonald CP, Lowe P, Roy A, et al. Evaluation of donor arm disinfection techniques. Vox Sang 2001;80:135-41.
25. Gibson T, Norris W. Skin fragments removed by injection needles. Lancet 1958;2:983-5.
26. Ness PM, Perkins HA. Transient bacteremia after dental procedures and other minor manipulations. Transfusion 1980;20:82-5.
27. Holden F, Foley M, Gerard D, et al. Coagulase-negative staphylococcal contamination of whole blood and its components: the effects of WBC reduction. Transfusion 2000;40:1508-13.
28. Hogman CF, Gong J, Hambraeus A, Johansson CS, Eriksson L. The role of white cells in the transmission of Yersinia enterocolitica in blood components. Transfusion 1992;32:654-7.
29. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001;41:857-61.
30. Marrow JF, Braine HG, Kicklers TS, et al. Septic reactions to platelet transfusions. JAMA 1991;266:555-8.
31. Chiu EK, Yuen KY, Lie AK, et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994;34:950-4.
32. Wagner SJ, Robinette D. Evaluation of swirling, pH, and glucose tests for the detection of bacterial contamination in platelet concentrates. Transfusion 1996;36:989-93.
33. Liu H, Yuen K, Cheng TS, et al. Reduction of platelet transfusion-associated sepsis by short-term bacterial culture. Vox Sang 1999;77:1-5.
34. Hess JR, Rugg AD, Knapp JF, et al. Successful storage of RBCs for 9 weeks in a new additive solution. Transfusion 2000;40:1007-11.
35. Hess JR, Rugg N, Knapp AD, et al. Successful storage of RBCs for 10 weeks in a new additive solution. Transfusion 2000;40:1012-6.
36. Bruneau CB, Perez P, Chassaigne M, et al. Efficacy of a new collection procedure for preventing bacterial contamination of whole blood products. Transfusion 2001;41;74-81.
37. de Korte D, Marcelis JH. Soeterboek. Determination of the degree of bacterial contamination of who-blood collections using an automated microbe-detections system. Transfusion 2001;41:815-8.
38. Brecher ME, Wong ECC, Chen SE, et al. Antibiotic-labeled probes and microvolume florimetry for the rapid detection of bacterial contamination in platelet components: a preliminary report. Transfusion 2000;40:411-3.
39. Yomtovian R, Lazarus HM, Goodnough LT, et al. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993;33:902-9.
40. AuBuchon JP, Cooper LK, Leach MF, et al. Bacterial culture of platelet units and extension of storage to 7 days. Transfusion 2001;41(Suppl):1S.
41. Hillyer CD, Emmens RK, Zago-Novaretti M, et al. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units. Transfusion 1994;34:929-34.
42. Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal leukoreduction: a consensus statement. Transfusion 2001;41:560-9.
43. Preciosities JK. The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? Transfus Med Rev 2000;14:126.
44. Alfieri C, Tanner J, Carpentier L, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain form the recipient's blood and oropharynx. Blood 1996;87:812-7.
45. Luppi M, Barozzi P, Santagostino G, et al. Molecular evidence of organ-related transmission of Kaposi sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood 2000;96:3279-81.
46. Challine D, Roudot-Thoraval F, Sarah T, et al. Seroprevalence of human herpes virus 8 in populations at high or low risk of transfusion, graft, or sexual transmission of virus. Transfusion 2001;41:1120-5.
47. McQuiston JH, Childs JE, Chamberland ME, et al. Transmission of tick-borne agents of disease by blood transfusion: a review of known and potential risks in the United States. Transfusion 2000;40:274-84.
48. Moraes-Souza H, Bordin JO, Bardossy L. Prevention of transfusion-associated Chagas' disease: efficacy of white cell-reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion 1995;35:723-6.
49. Tinmouth A, Chin-Yee I. The clinical consequences of the red cell storage lesion. Transfus Med Rev 2001;15:91-107.
50. Mungai M, Tegtmeier G, Chamberland M, et al. Transfusion transmitted malaria in the United States from 1963 through 1993. N Engl J Med 2001;344:1973-8.
51. Leiby DA. Parasites and other emergent infectious agents. In: Blood safety for the new millennium. Stramer SL, editor. Bethesda (MD): American Association of Blood Banks; 2001. p. 55-78.
52. Wells GM, Woodward TE, Fiset P, et al. Rocky Mountain spotted fever caused by a blood transfusion. JAMA 1978;239:2763-5.
53. Prusiner SB. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516-25.
54. Roos RP. Controlling prion diseases. N Engl J Med 2001;344:1548-50.
55. Volkel D, Zimmermann K, Zerr I, et al. Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion 2001;41:441-8.
56. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000;16:999-1000.
57. Opeiz G, Sengar DP, Mickey MR, et al. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5:253-9.
58. Vamvakas EC, Blajchman MA, editors. Immunomodulatory effects of blood transfusion. Bethesda (MD): American Association of Blood Banks; 1999.
59. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompentent transfusion recipients: frequent long-term microchimerism in severe trauma patients. Blood 1999;93:3127-39.
60. Yasuura K, Okamoto H, Matsuura A. Transfusion-associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg (Torino) 2000;41:377-80.
61. Rebulla P, Modell B. Transfusion requirement and effects in patients with thalassemia major. Lancet 1991;337:277-80.
62. Hobiers JGA, Brand A, van de Watering LMG, et al. Randomized controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-8.
63. Busch ORC, Hop WCJ, Marquet RL, et al. Autologous blood and infections after colorectal surgery. Lancet 1994;343:668-9.
64. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001;41:691-712.
65. Transfusion related acute lung injury (letter). Available at: www.fda.gov/cber/ltr/trali101901.htm. Accessed October 19, 2001.
66. Bamard RD. Indiscriminate transfusion: a critique of case reports illustration hypersensitivity reactions. The New York State Journal of Medicine 1951;51:2399-402.
67. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573-7.
68. Silliman CC. Transfusion-related acute lung injury. Transfus Med Rev 1999;13:177-86.
69. Rizk A, Gorson KC, Kenny L, et al. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001;41:264-8.
70. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: pre-storage leukocyte reduction of whole blood and blood components intended for transfusion. Federal Register, January 2001.
71. Yomtovian R, Gernsheimer T, Assmann SF, et al. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001;41:1030-6.
72. Nightingale SD. Universal WBC reduction. Transfusion 2001;41:1306-9.
73. Morgenthaler J. Securing viral safety for plasma derivatives. Transfus Med Rev 2001;15:224-33.
74. Lin L, Cook DN, Wiesehahn R, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
75. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93:3140-7.
76. Simon ER, Chapman RG, Finch CA, et al. Adenine in red cell preservation. J Clin Invest 1962;41:351.
77. Zuck TF, Bensinger TA, Peck CC, et al. The in vivo survival of red blood cells stored in modified CPD with adenine: report of a multi-institutional cooperative effort. Transfusion 1977;17:374.
78. Hogman CF, Kuntson F. Standardized units of RBC's: is it time for implementation? Transfusion 2000;40:330-4.
79. Stowell CP, Levin J, Spiess BD. Progress in the development of RBC substitutes. Transfusion 2001;41:287-99.
80. Gould SA, Rosen AL, Sehgal LR, et al. Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 1986;314:1653-6.
81. CBER. Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Transfusion 1991;31:369-71.
82. Jeong ST, Byun SM. Decreased agglutinability of methoxy-polyethylene glycol attached red blood cells: significance as a blood substitute. Artif Cells Blood Substit Immobil Biotechnol 1996;24:503-11.
83. Bradley AJ, Test ST, Murad KL, et al. Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBC's. Transfusion 2001;41:1225-33.